Zimmer Biomet Holdings Inc

Surgical equipment and consumables stocks tracked by StockStory delivered a strong second quarter, with group revenues beating analysts' consensus estimates by 1.6%. STERIS reported revenues of $1.49 billion, up 7.3% year on year, in line with expectations but with the weakest performance against analyst estimates of the group. Solventum posted revenues of $2.21 billion, up 2.2% year on year, outperforming expectations by 2.5% and delivering the biggest analyst estimate beat among its peers. Zimmer Biomet reported revenues of $2.18 billion, up 4.8% year on year, exceeding expectations by 2%, while CONMED reported revenues of $343.5 million, flat year on year, beating expectations by 1.8%. BD reported revenues of $4.98 billion, up 5.4% year on year, topping expectations by 2%.

Long Cast Advisers highlighted Pro-Dex, Inc. as a top position in its Q2 2026 investor letter, citing the potential for exceptional operating cash flow transformation if Zimmer Biomet succeeds with the commercialization of its mBos surgical robot. The firm estimates that Zimmer's purchase of Monogram included contingent valuation rights paying $3.41 per share annually from 2028 to 2030 if mBos gross revenues exceed certain hurdles, and it calculates that roughly 609 system sales would be needed to trigger the final CVR, a target it views as achievable given Stryker sold 860 Mako units in its first three years. Long Cast Advisers assumes four effectors per system sale and a capital sale price of around $1 million per machine, in line with the Mako platform. The adviser believes that once the system launches, Pro-Dex could see a substantial increase in corporate value, justifying its continued top position in the portfolio.

Zimmer Biomet raised its full-year 2026 guidance after reporting second-quarter net sales of $2.177 billion, up 4.8% on a reported basis. Adjusted EPS was $2.07, unchanged from a year earlier, while U.S. organic constant-currency sales rose 4.6%. Hip sales grew 5.1% and technology, data, bone cement and surgical sales surged 21.5%, driven by strong adoption of ROSA, TMINI and OrthoGrid systems. The company now expects organic constant-currency revenue growth of 2.25% to 3.25% for 2026, up from a prior range of 1% to 3%, and raised adjusted EPS guidance to $8.47 to $8.59. Zimmer Biomet also plans up to $1 billion in share repurchases this year, $250 million above its previous expectation.

Pacira BioSciences reported a second-quarter profit of $4.65 million, or $0.12 per share, swinging from a loss of $4.85 million, or $0.11 per share, a year earlier. Total revenue rose 6% to $192.40 million, driven by higher product sales and $1.91 million in royalty revenue. EXPAREL sales increased 3.4% to $147.82 million, while ZILRETTA sales edged up to $32.65 million. The company completed the divestiture of its Iovera business to Zimmer Biomet for $73.6 million in cash at closing, with potential milestone payments of up to $70 million. Following the divestiture, Pacira revised its full-year 2026 total revenue guidance to a range of $735 million to $760 million, down from the prior range of $745 million to $770 million, and projects EXPAREL net product sales of $600 million to $620 million.

Zimmer Biomet reported first-quarter revenues of $2.09 billion, up 9.3% year on year, making it the fastest-growing company among five surgical equipment and consumables stocks tracked. The result exceeded analysts' expectations by 0.9%, and the company also beat earnings per share estimates and full-year EPS guidance. CONMED posted revenues of $317 million, down 1.3% year on year but beating estimates by 2.1%, the largest beat in the group. STERIS reported $1.59 billion in revenues, up 7.3% and in line with expectations, while BD's revenues rose 5.2% to $4.71 billion, topping estimates by 0.8%. Solventum's revenues declined 3.1% to $2.01 billion, surpassing estimates by 1.9% but recording the slowest revenue growth among the peers.

Zimmer Biomet Holdings has appointed Chintan Desai as president of its Asia Pacific region, effective July 14, 2026, succeeding Sang Yi after a transition ending August 28, 2026. Desai brings three decades of MedTech and regional leadership experience from Alcon and GE Healthcare. The appointment aligns with the company's robotics-led growth strategy but does not alter near-term focus on robotics execution and acquisition integration. The upcoming Q2 2026 earnings call on August 5 is expected to provide updates on Asia Pacific and robotics contributions.

The global surgical robots market is projected to grow from USD 13.69 billion in 2025 to USD 27.14 billion by 2030, at a compound annual growth rate of 14.7%, according to a new report by MarketsandMarkets. Growth is driven by increasing demand for minimally invasive surgeries, rising surgical volumes linked to chronic diseases and an aging population, and advances in robotic platforms, 3D visualization, AI-assisted navigation, and surgical instrumentation. Instruments and accessories represent the largest offering segment, general surgery is the largest application segment, and hospitals and clinics are the largest end-user segment. Asia Pacific is expected to be the fastest-growing regional market, with key players including Intuitive Surgical, Stryker Corporation, Medtronic, Smith+Nephew, and Zimmer Biomet.

Zimmer Biomet has agreed to acquire Pacira BioSciences' FDA-cleared iovera pain relief device in a deal valued at up to $140 million, including $70 million upfront and future milestone payments. The agreement also includes a collaboration to advance the iovera spasticity program, extending Zimmer Biomet's reach into non-opioid pain management and neuromuscular conditions. The transaction is expected to close in the third quarter of 2026, subject to customary conditions. Zimmer Biomet's recently renewed $2.75 billion in revolving credit facilities provides liquidity to fund the acquisition alongside other corporate needs. The move reflects continued portfolio building around the full episode of orthopedic care, complementing its existing joint replacement and extremities products.